



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/575,779

09/28/2007

Michael Teifel

40695.00600

9429

38647

7590

11/18/2010

MILBANK, TWEED, HADLEY & MCCLOY LLP
INTERNATIONAL SQUARE BUILDING
1850 K STREET, N.W., SUITE 1100
WASHINGTON, DC 20006

EXAMINER

SCHULTZ, JAMES

ART UNIT

PAPER NUMBER

1633

MAIL DATE

DELIVERY MODE

11/18/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10575779	9/28/07	TEIFEL ET AL.	062587-5007

MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004

EXAMINER

James (Doug) Schultz, PhD

ART UNIT	PAPER
1633	20101117

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on August 6, 2010 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): applicants response declines to address the merits of any of the provisional double patenting rejections set forth in the previous action, which runs afoul of applicants' requirements under 37 CFR 1.111(b) to reply to each and every ground of objection and rejection. Also, applicants were notified in the non-final action mailed April 6, 2010 that any claim amendment to require the examination of any specific cancers or chemotherapeutic agents would require election of a single cancer and/or a single chemotherapeutic agent. Such amendments have been supplied in the applicants response of August 6, 2010 but with no accompanying election. See official action of April 6, 2010 and 37 CFR 1.111(b). Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).**

/James (Doug) Schultz, PhD/
Primary Examiner, Art Unit 1633